GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats

Ma,Jingjing; Shi,Min; Zhang,Xiangcheng; Liu,Xiaoning; Chen,Juan; Zhang,Ridong; Wang,Xingzhou; Zhang,Hong

doi:10.3892/ijmm.2018.3509

GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats

Authors:
- Jingjing Ma
- Min Shi
- Xiangcheng Zhang
- Xiaoning Liu
- Juan Chen
- Ridong Zhang
- Xingzhou Wang
- Hong Zhang
View Affiliations

Affiliations: Department of Endocrinology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: February 23, 2018 https://doi.org/10.3892/ijmm.2018.3509
Pages: 2977-2985

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the mechanism of glucagon‑like peptide‑1 receptor (GLP‑1R) agonists in the progression of diabetic peripheral neuropathy (DPN) in streptozotocin (STZ)‑induced diabetic rats, through inflammatory signaling pathways. The DPN rat model was generated by intraperitoneal injection of STZ and then treated with the GLP‑1R agonist liraglutide or saline for 8 weeks. These animals were randomly divided into 4 groups (10 rats in each): The normal control + saline group, the normal control + liraglutide group, the diabetic + saline (DM) group and the diabetic + liraglutide (DML) group. The nerve conduction velocity (NCV) in the sciatic nerves of the rats was monitored over a period of 8 weeks. Peripheral serum was obtained for the measurement of blood glucose, tumor necrosis factor‑α (TNF‑α), interleukin‑6 (IL‑6) and IL‑1β level. The protein levels of phosphorylated (p‑) and total extracellular signal‑regulated kinase, c‑Jun NH2‑terminal kinases, p38 mitogen‑activated protein kinases (MAPK), and nuclear and cytoplasmic nuclear factor‑κB (NF‑κB) were measured through western blot analysis. Sciatic nerve mRNA expression levels of proinflammatory chemokines (TNF‑α, IL‑6 and IL‑1β), chemokines [monocyte chemoattractant protein‑1 (MCP‑1)], adhesion molecules [intercellular adhesion molecule 1 (ICAM‑1)], neurotrophic factors [neuritin, nerve growth factor (NGF) and neuron‑specific enolase (NSE)] and NADPH oxidase 4 (NOX4) were evaluated by reverse transcription-quantitative polymerase chain reaction. Subsequent to 8 weeks of treatment with liraglutide, the density of myelin nerve fibers was partially restored in the DML group. The delayed motor NCV and sensory NCV in the DML group were improved. The IOD value of NOX4 staining in the DML group (24.43±9.01) was reduced compared with that in the DM group (56.60±6.91). The levels of TNF‑α, IL‑1β and IL‑6 in the peripheral serum of the DML group were significantly suppressed compared with those of the DM group. It was also observed that the mRNA expression levels of TNF‑α, IL‑6, IL‑1β, MCP‑1, ICAM‑1 and NOX4 in the sciatic nerve were attenuated in the DML group. The mRNA expression of neuritin and NGF was significantly increased in the DML group compared with that of the DM group; NSE was reduced in the sciatic nerves of the DML group compared with that of the DM group. Additionally, the protein expression of p‑p38 MAPK and NF‑κB in the DML group was significantly suppressed. These data demonstrated that GLP‑1R agonists may prevent nerve dysfunction in the sciatic nerves of diabetic rats via p38 MAPK/NF‑κB signaling pathways independent of glycemic control. GLP‑1R agonists may be a useful therapeutic strategy for slowing the progression of DPN.

View Figures

View References

1	Sandireddy R, Yerra VG, Areti A, Komirishetty P and Kumar A: Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. Int J Endocrinol. 2014:6749872014. View Article : Google Scholar : PubMed/NCBI
2	O'Brien PD, Sakowski SA and Feldman EL: Mouse models of diabetic neuropathy. ILAR J. 54:259–272. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR and Jeong GH: Recurrent insulin autoimmune syndrome caused by α-Lipoic acid in type 2 diabetes. Endocrinol Metab (Seoul). 28:326–330. 2013. View Article : Google Scholar
4	Oyenihi AB, Ayeleso AO, Mukwevho E and Masola B: Antioxidant strategies in the management of diabetic neuropathy. BioMed Res Int. 2015:5150422015. View Article : Google Scholar : PubMed/NCBI
5	Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, Wijesekara N, Martins RN, Fraser PE and Newsholme P: Inflammation and oxidative stress: The molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediators Inflamm. 2015:1058282015. View Article : Google Scholar : PubMed/NCBI
6	Xiao Q, Yang YA, Zhao XY, He LS, Qin Y, He YH, Zhang GP and Luo JD: Oxidative stress contributes to the impaired sonic hedgehog pathway in type 1 diabetic mice with myocardial infarction. Exp Ther Med. 10:1750–1758. 2015. View Article : Google Scholar : PubMed/NCBI
7	Yang XW, Liu FQ, Guo JJ, Yao WJ, Li QQ, Liu TH and Xu LP: Antioxidation and anti-inflammatory activity of Tang Bi Kang in rats with diabetic peripheral neuropathy. BMC Complement Altern Med. 15:662015. View Article : Google Scholar : PubMed/NCBI
8	Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F, Shinko A, Wakamori T, Toyoshima A, Takeuchi H, et al: Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci. 14:21513–21524. 2013. View Article : Google Scholar : PubMed/NCBI
9	Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T and Shimomura I: Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: A pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 10:1092011. View Article : Google Scholar : PubMed/NCBI
10	Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, Feldman EL and Pop-Busui R: Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: Results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications. 29:1287–1294. 2015. View Article : Google Scholar : PubMed/NCBI
11	Jolivalt CG, Fineman M, Deacon CF, Carr RD and Calcutt NA: GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab. 13:990–1000. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS and Park TS: Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. 164:1410–1420. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ganesh Yerra V, Negi G, Sharma SS and Kumar A: Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy. Redox Biol. 1:394–397. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ramesh G, MacLean AG and Philipp MT: Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013:4807392013. View Article : Google Scholar : PubMed/NCBI
15	Livak and Schmittgen: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Höke A: Animal models of peripheral neuropathies. Neurotherapeutics. 9:262–269. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chapter MC, White CM, DeRidder A, Chadwick W, Martin B and Maudsley S: Chemical modification of class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther. 125:39–54. 2010. View Article : Google Scholar
18	Douglas DS and Popko B: Mouse forward genetics in the study of the peripheral nervous system and human peripheral neuropathy. Neurochem Res. 34:124–137. 2009. View Article : Google Scholar :
19	Edwards JL, Vincent AM, Cheng HT and Feldman EL: Diabetic neuropathy: Mechanisms to management. Pharmacol Ther. 120:1–34. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lupachyk S, Stavniichuk R, Komissarenko JI, Drel VR, Obrosov AA, El-Remessy AB, Pacher P and Obrosova IG: Na⁺/H⁺-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis. Int J Mol Med. 29:989–998. 2012.PubMed/NCBI
21	Tesfaye S, Boulton AJ and Dickenson AH: Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 36:2456–2465. 2013. View Article : Google Scholar : PubMed/NCBI
22	Karamoysoyli E, Burnand RC, Tomlinson DR and Gardiner NJ: Neuritin mediates nerve growth factor-induced axonal regeneration and is deficient in experimental diabetic neuropathy. Diabetes. 57:181–189. 2008. View Article : Google Scholar
23	Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M and Loba J: Serum levels of inflammatory markers in depressed elderly patients with diabetes and mild cognitive impairment. PLoS One. 10:e01204332015. View Article : Google Scholar : PubMed/NCBI
24	Zong H, Ward M, Madden A, Yong PH, Limb GA, Curtis TM and Stitt AW: Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia. 53:2656–2666. 2010. View Article : Google Scholar : PubMed/NCBI
25	Heni M, Kullmann S, Gallwitz B, Häring HU, Preissl H and Fritsche A: Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans. Mol Metab. 4:971–976. 2015. View Article : Google Scholar
26	May AA and Woods SC: Is endogenous GLP-1 a major influence on the orbitofrontal cortex? Mol Metab. 4:977–978. 2015. View Article : Google Scholar
27	Meng J, Ma X, Wang N, Jia M, Bi L, Wang Y, Li M, Zhang H, Xue X, Hou Z, et al: Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin. Stem Cell Reports. 6:6332016. View Article : Google Scholar
28	Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sato K, Fukuzawa Y and Yoneda M: Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J gastroenterol. 22:2512–2523. 2016. View Article : Google Scholar : PubMed/NCBI
29	Seino Y and Yabe D: Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig. 4:108–130. 2013. View Article : Google Scholar : PubMed/NCBI
30	Greig NH, Tweedie D, Rachmany L, Li Y, Rubovitch V, Schreiber S, Chiang YH, Hoffer BJ, Miller J, Lahiri DK, et al: Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement. 10(Suppl): S62–S75. 2014. View Article : Google Scholar : PubMed/NCBI
31	Harkavyi A and Whitton PS: Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol. 159:495–501. 2010. View Article : Google Scholar : PubMed/NCBI
32	Janssens J, Etienne H, Idriss S, Azmi A, Martin B, Maudsley S and Systems-Level G: Systems-level G protein-coupled receptor therapy across a neurodegenerative continuum by the GLP-1 receptor system. Front Endocrinol (Lausanne). 5:1422014.
33	Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, et al: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 106:1285–1290. 2009. View Article : Google Scholar : PubMed/NCBI
34	Salcedo I, Tweedie D, Li Y and Greig NH: Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 166:1586–1599. 2012. View Article : Google Scholar : PubMed/NCBI
35	Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA and Greig NH: Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 203:293–301. 2007. View Article : Google Scholar :
36	Katagi M, Terashima T, Okano J, Urabe H, Nakae Y, Ogawa N, Udagawa J, Maegawa H, Matsumura K, Chan L, et al: Hyperglycemia induces abnormal gene expression in hematopoietic stem cells and their progeny in diabetic neuropathy. FEBS Lett. 588:1080–1086. 2014. View Article : Google Scholar : PubMed/NCBI
37	Yan LJ: Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. J Diabetes Res. 2014:1379192014. View Article : Google Scholar : PubMed/NCBI
38	Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P and Tomlinson DR: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. 15:2508–2514. 2001. View Article : Google Scholar : PubMed/NCBI
39	Jiang C and Salton SR: The role of neurotrophins in major depressive disorder. Transl Neurosci. 4:46–58. 2013. View Article : Google Scholar : PubMed/NCBI
40	Li J, Zhang H, Xie M, Yan L, Chen J and Wang H: NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes Care. 36:3405–3410. 2013. View Article : Google Scholar : PubMed/NCBI